[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @MarketPulse360 Market Pulse 360° Market Pulse 360° posts on X about $phge, $iinn, nasdaq, india the most. They currently have XX followers and XX posts still getting attention that total XX engagements in the last XX hours. ### Engagements: XX [#](/creator/twitter::1517444811296587777/interactions)  - X Week XXX +375% - X Month XXX +97% - X Months XXXXX +633% - X Year XXXXXX +418% ### Mentions: X [#](/creator/twitter::1517444811296587777/posts_active)  - X Week X +600% - X Month XX +220% - X Months XX +88% - X Year XX +148% ### Followers: XX [#](/creator/twitter::1517444811296587777/followers)  - X Week XX no change - X Month XX +11% - X Months XX +35% ### CreatorRank: undefined [#](/creator/twitter::1517444811296587777/influencer_rank)  ### Social Influence [#](/creator/twitter::1517444811296587777/influence) --- **Social category influence** [exchanges](/list/exchanges) XXXX% [finance](/list/finance) XXXX% [countries](/list/countries) XXXX% [stocks](/list/stocks) XXXX% **Social topic influence** [$phge](/topic/$phge) 16.67%, [$iinn](/topic/$iinn) 8.33%, [nasdaq](/topic/nasdaq) 8.33%, [india](/topic/india) 8.33%, [dr reddys](/topic/dr-reddys) 8.33%, [$rdy](/topic/$rdy) 8.33%, [sanofi](/topic/sanofi) 8.33%, [rat](/topic/rat) 8.33%, [weight loss](/topic/weight-loss) 8.33%, [$ptnt](/topic/$ptnt) XXXX% **Top assets mentioned** [Dr. Reddy's Laboratories Limited American Depositary Shares (RDY)](/topic/$rdy) [Sanofi (SNY)](/topic/sanofi) ### Top Social Posts [#](/creator/twitter::1517444811296587777/posts) --- Top posts by engagements in the last XX hours "Inspira Technologies Regains Nasdaq Compliance: Minimum Bid Price Achieved $IINN ➡ Inspira Technologies received notification from Nasdaq confirming compliance with the minimum bid price requirement. ➡ The company's common shares maintained a closing bid price at or above $XXXX per share for XX consecutive business days. ➡ According to the announcement Inspira's CEO Dagi Ben-Noon views this compliance as a reflection of market confidence in the company's strategic direction. ➡ Inspira is focusing on global distribution and execution leveraging achievements like a large commercial order and"  [@MarketPulse360](/creator/x/MarketPulse360) on [X](/post/tweet/1946192967980462470) 2025-07-18 12:58:56 UTC XX followers, XX engagements "Dr. Reddy's Launches Sanofi's Beyfortus in India for RSV Prevention #DRREDDY $RDY ➡ Dr. Reddys Laboratories has launched Beyfortus (nirsevimab) in India a preventive treatment for Respiratory Syncytial Virus (RSV) in infants following an expanded partnership with Sanofi. ➡ RSV is a significant yet underreported health crisis in India causing many respiratory infections in infants with experts reporting over 2000 child deaths in 2024 from Kolkata Bengaluru and Mumbai alone. ➡ According to the Article Beyfortus launch aligns with Dr. Reddy's dual-track growth strategy strengthening its core"  [@MarketPulse360](/creator/x/MarketPulse360) on [X](/post/tweet/1945970502436020389) 2025-07-17 22:14:56 UTC XX followers, XXX engagements "BiomX's Phase 2b Trial Begins Analyst Reiterates $XX Target $PHGE ➡ BiomX initiated patient dosing in Phase 2b trial for BX004 targeting lung infections in cystic fibrosis patients. ➡ H.C. Wainwright reaffirmed a Buy rating and $XX price target for BiomX citing confidence in its dual-asset approach. ➡ Phase 1b/2a trial of BX004 showed XXXX% of patients completely cleared chronic Pseudomonas aeruginosa infections. ➡ The Phase 2b study will evaluate approximately XX patients over X weeks with topline results expected Q1 2026. ➡ BiomX's programs address unmet needs in diabetic foot osteomyelitis"  [@MarketPulse360](/creator/x/MarketPulse360) on [X](/post/tweet/1946259910141804881) 2025-07-18 17:24:56 UTC XX followers, XX engagements "BiomX Initiates Phase 2b Trial for BX004 a Potential Game-Changer $PHGE ➡ BiomX has dosed the first patient in its Phase 2b trial for BX004 targeting Pseudomonas aeruginosa in cystic fibrosis patients. ➡ The company's phage therapy approach aims to combat antibiotic-resistant infections with promising Phase 1b/2a results showing complete bacterial clearance in some patients. One patient according to the article had been infected for XX years before achieving complete clearance. ➡ BX004 has received FDA Fast Track and Orphan Drug designations potentially accelerating its path to market;"  [@MarketPulse360](/creator/x/MarketPulse360) on [X](/post/tweet/1944761171925496244) 2025-07-14 14:09:29 UTC XX followers, XXX engagements "$PTNT Oral MC4R Agonist PL7737 Shows Positive Preclinical Data in Obesity Model ➡ According to the announcement Palatin Technologies' oral MC4R agonist PL7737 demonstrated significant weight loss in preclinical studies using a diet-induced obese rat model. ➡ Monotherapy with oral PL7737 resulted in rapid weight loss with a high dose achieving XX% weight loss after just X days of treatment based on the announcement. ➡ The combination of oral PL7737 and tirzepatide showed additive effects leading to a XX% weight loss with the high dose combination according to the announcement. ➡ Palatin is"  [@MarketPulse360](/creator/x/MarketPulse360) on [X](/post/tweet/1945091851066695844) 2025-07-15 12:03:30 UTC XX followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@MarketPulse360 Market Pulse 360°
Market Pulse 360° posts on X about $phge, $iinn, nasdaq, india the most. They currently have XX followers and XX posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXX +375%
- X Month XXX +97%
- X Months XXXXX +633%
- X Year XXXXXX +418%
Mentions: X #
- X Week X +600%
- X Month XX +220%
- X Months XX +88%
- X Year XX +148%
Followers: XX #
- X Week XX no change
- X Month XX +11%
- X Months XX +35%
CreatorRank: undefined #
Social Influence #
Social category influence exchanges XXXX% finance XXXX% countries XXXX% stocks XXXX%
Social topic influence $phge 16.67%, $iinn 8.33%, nasdaq 8.33%, india 8.33%, dr reddys 8.33%, $rdy 8.33%, sanofi 8.33%, rat 8.33%, weight loss 8.33%, $ptnt XXXX%
Top assets mentioned Dr. Reddy's Laboratories Limited American Depositary Shares (RDY) Sanofi (SNY)
Top Social Posts #
Top posts by engagements in the last XX hours
"Inspira Technologies Regains Nasdaq Compliance: Minimum Bid Price Achieved $IINN ➡ Inspira Technologies received notification from Nasdaq confirming compliance with the minimum bid price requirement. ➡ The company's common shares maintained a closing bid price at or above $XXXX per share for XX consecutive business days. ➡ According to the announcement Inspira's CEO Dagi Ben-Noon views this compliance as a reflection of market confidence in the company's strategic direction. ➡ Inspira is focusing on global distribution and execution leveraging achievements like a large commercial order and"
@MarketPulse360 on X 2025-07-18 12:58:56 UTC XX followers, XX engagements
"Dr. Reddy's Launches Sanofi's Beyfortus in India for RSV Prevention #DRREDDY $RDY ➡ Dr. Reddys Laboratories has launched Beyfortus (nirsevimab) in India a preventive treatment for Respiratory Syncytial Virus (RSV) in infants following an expanded partnership with Sanofi. ➡ RSV is a significant yet underreported health crisis in India causing many respiratory infections in infants with experts reporting over 2000 child deaths in 2024 from Kolkata Bengaluru and Mumbai alone. ➡ According to the Article Beyfortus launch aligns with Dr. Reddy's dual-track growth strategy strengthening its core" @MarketPulse360 on X 2025-07-17 22:14:56 UTC XX followers, XXX engagements
"BiomX's Phase 2b Trial Begins Analyst Reiterates $XX Target $PHGE ➡ BiomX initiated patient dosing in Phase 2b trial for BX004 targeting lung infections in cystic fibrosis patients. ➡ H.C. Wainwright reaffirmed a Buy rating and $XX price target for BiomX citing confidence in its dual-asset approach. ➡ Phase 1b/2a trial of BX004 showed XXXX% of patients completely cleared chronic Pseudomonas aeruginosa infections. ➡ The Phase 2b study will evaluate approximately XX patients over X weeks with topline results expected Q1 2026. ➡ BiomX's programs address unmet needs in diabetic foot osteomyelitis" @MarketPulse360 on X 2025-07-18 17:24:56 UTC XX followers, XX engagements
"BiomX Initiates Phase 2b Trial for BX004 a Potential Game-Changer $PHGE ➡ BiomX has dosed the first patient in its Phase 2b trial for BX004 targeting Pseudomonas aeruginosa in cystic fibrosis patients. ➡ The company's phage therapy approach aims to combat antibiotic-resistant infections with promising Phase 1b/2a results showing complete bacterial clearance in some patients. One patient according to the article had been infected for XX years before achieving complete clearance. ➡ BX004 has received FDA Fast Track and Orphan Drug designations potentially accelerating its path to market;" @MarketPulse360 on X 2025-07-14 14:09:29 UTC XX followers, XXX engagements
"$PTNT Oral MC4R Agonist PL7737 Shows Positive Preclinical Data in Obesity Model ➡ According to the announcement Palatin Technologies' oral MC4R agonist PL7737 demonstrated significant weight loss in preclinical studies using a diet-induced obese rat model. ➡ Monotherapy with oral PL7737 resulted in rapid weight loss with a high dose achieving XX% weight loss after just X days of treatment based on the announcement. ➡ The combination of oral PL7737 and tirzepatide showed additive effects leading to a XX% weight loss with the high dose combination according to the announcement. ➡ Palatin is" @MarketPulse360 on X 2025-07-15 12:03:30 UTC XX followers, XX engagements